All In Biotech

Drug Trial Radar · NCT05373264

HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life

Last checked: Nov 20, 2026Latest source record: Aug 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Jul 31, 2024

Primary completion

Jul 2030

Study completion Jul 2031

Sponsor

Lead sponsor
University Medical Center GroningenAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 13, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive formation of renal cysts which ultimately lead to a loss of renal function. Tolvaptan (a V2R antagonist) is currently the only effective treatment for preserving renal function in ADPKD. However, side-effects such as polyuria limit its tolerability and thereby the therapeutic potential. This study will test whether co-administration with hydochlorothiazide can improve V2RA efficacy (slowing kidney function decline) and tolerability (quality of life) in ADPKD. Approximately 300 patients will be enrolled.

Conditions

  • ADPKD

Interventions

  • Hydrochlorothiazide 25 mgDrug

    An oral capsule containing 25mg of hydrochlorothiazide

  • PlaceboDrug

    A matching oral capsule containing placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes in kidney function declineTime frame: 156 weeks

Locations

25 sites in 7 countries. Site status is shown where the registry gives one.

  • Uniklinikum Graz

    Graz, Austria · Recruiting

  • Medizinische Universität Innsbruck

    Innsbruck, Austria · Recruiting

  • Universitair Ziekenhuis Antwerpen (UZA)

    Antwerp, Belgium · Recruiting

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium · Recruiting

  • University Hospital Leuven

    Leuven, Belgium · Recruiting

  • Hôpital Pellegrin (CHU Bordeaux)

    Bordeaux, France · Recruiting

  • Hospital La Cavale Blanche

    Brest, France · Recruiting

  • Centre Hôpital Universitaire de Lyon

    Lyon, France · Recruiting

  • Hôpitaux de Brabois (CHRU)

    Nancy, France · Recruiting

  • Necker-Enfants Malades Hospital

    Paris, France · Recruiting

  • Charité University Hospital

    Berlin, Germany · Recruiting

  • University Hospital Cologne

    Cologne, Germany · Recruiting

  • Med. Klinik und Poliklinik III, Universitätsklinikum Dresden.

    Dresden, Germany · Recruiting

  • Universitätsklinikum Leipzig

    Leipzig, Germany · Recruiting

  • Amsterdam University Medical Center

    Amsterdam, Netherlands · Recruiting

  • University Medical Center Groningen

    Groningen, Netherlands · Recruiting

  • Erasmus University Medical Center

    Rotterdam, Netherlands · Recruiting

  • Hospital Universitario Mancha Centro

    Alcázar de San Juan, Spain · Recruiting

  • Fundación Puigvert

    Barcelona, Spain · Recruiting

  • Hospital Universitario Vall D'Hebron

    Barcelona, Spain · Recruiting

  • La Fundación Jiménez Díaz

    Madrid, Spain · Recruiting

  • Universitätsspital Bern (Inselsspital)

    Bern, Switzerland · Recruiting

  • Hôpital Fribourgeois (HFR)

    Fribourg, Switzerland · Recruiting

  • Hôpitaux Universitaires de Genève (HUG)

    Geneva, Switzerland · Recruiting

  • Universitätsspital Zürich (USZ)

    Zurich, Switzerland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.